Valuation: Beta Bionics, Inc.

Market Cap 770M 673M 621M 573M 1.08B 74.2B 1.1B 7.43B 2.92B 36.34B 2.89B 2.83B 125B P/E 2026 *
-7.75x
P/E 2027 * -7.76x
Enterprise Value 596M 521M 480M 443M 835M 57.36B 853M 5.74B 2.26B 28.09B 2.24B 2.19B 96.71B EV / Sales 2026 *
4.47x
EV / Sales 2027 * 3.73x
Free-Float
98.91%
Yield 2026 *
-
Yield 2027 * -
1 day+2.31%
1 week+1.53%
Current month+10.34%
1 month+24.57%
3 months+33.20%
6 months-6.54%
Current year-43.26%
1 week 15.79
Extreme 15.79
17.87
1 month 13.02
Extreme 13.02
17.87
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap.
29/06/26 Fiscal year

Chief Financial Officer

14,688 0.0330%
29/06/26 Fiscal year

Chief Financial Officer

14,688 0.0330%
24/06/26 Sell

Executive/Senior Manager

-1,258 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
+2.31%+1.53%+27.23% - 770M
-1.97%+1.03%+28.39%+1.68% 198B
-0.58%+2.40%+7.25%-15.35% 144B
-14.15%-15.08%-33.40%-2.68% 122B
-1.32%-1.65%-57.52%-16.63% 65.44B
-2.40%-7.03%+12.08%-6.81% 49.36B
-0.11%+1.53%-23.83%-30.51% 44.74B
-3.41%-2.11%+15.33%+9.95% 37.13B
-2.44%-1.98%+28.33%+35.71% 36.23B
-1.86%-2.39%-22.85%-10.01% 28.7B
Average -2.59%-1.93%-1.90%-3.85% 72.69B
Weighted average by Cap. -3.69%-1.84%-0.96%-4.99%

Financials

2026 *2027 *
Net sales 133M 116M 108M 99.09M 187M 12.84B 191M 1.28B 505M 6.29B 501M 490M 21.64B 180M 157M 145M 133M 252M 17.29B 257M 1.73B 681M 8.47B 674M 659M 29.15B
Net income -99.93M -87.33M -80.58M -74.28M -140M -9.62B -143M -963M -379M -4.71B -375M -367M -16.22B -99.35M -86.82M -80.11M -73.85M -139M -9.57B -142M -958M -377M -4.69B -373M -365M -16.13B
Net Debt -175M -153M -141M -130M -245M -16.83B -250M -1.68B -663M -8.24B -656M -642M -28.38B -101M -88.36M -81.53M -75.15M -142M -9.74B -145M -975M -383M -4.77B -380M -371M -16.42B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
17/07/26 $17.29 +2.31% 1,233,773
16/07/26 $16.90 +0.24% 687,750
15/07/26 $16.86 0.00% 1,746,679
14/07/26 $16.86 -0.53% 1,476,016
13/07/26 $16.95 -0.47% 1,015,548
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
17.29USD
Average target price
19.80USD
Spread / Average Target
+14.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock